GlobeNewswire Inc | Oct 22, 2020 04:05PM EDT

October 22, 2020

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Companys immuno-oncology team will provide an overview of the companys early-stage immuno-oncology research, specifically the AL008 development program, at two upcoming virtual scientific meetings.

AL008 is a novel, investigational, antibody product candidate targeting the CD47-SIRP-alpha (SIRP) pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. AL008 is a potential best-in-class SIRP inhibitor with a unique dual mechanism of action that noncompetitively antagonizes the CD47- SIRP pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a dont eat me signal) while also engaging and activating Fcg gamma receptor (FcggammaR) to promote immuno-stimulatory pathways that drive anti-tumor immunity.

The virtual scientific meetings include the:

-- Macrophage-Directed Therapies SummitDate and Time: Wednesday, October 28, 2020 at 10:30 a.m. ESTPresentation: A Novel Approach to Targeting the SIRP Checkpoint Pathway and FcggammaR SignalingPresenter: Spencer Liang, Ph.D., senior director and head of immuno-oncology

-- CD47|SIRP SummitDate and Time: Wednesday, November 4, 2020 at 4:30 p.m. ESTPanel: What are the Predictive Biomarkers Arising When Targeting CD47|SIRP Pathways?Presenter: Spencer Liang, Ph.D., senior director and head of immuno-oncologyDate and Time: Thursday, November 5, 2020 at 11:35 a.m. ESTPresentation: An Insight into Alectors Novel Approach to Drive Anti-Tumor Immunity Targeting CD47|SIRP PathwaysPresenter: Andrew Picentic, Ph.D., senior staff scientist and group leaderDate and Time: Thursday, November 5, 2020 at 11:35 a.m. ESTPanel: How Can We Manage Toxicity and Improve Clinical Practice in Targeting CD47|SIRP Pathways?Presenter: Daniel Maslyar, M.D., vice president of clinical development, oncology

We are pleased to be highlighting the progress of our early-stage immuno-oncology programs at two notable research forums, said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. Despite the tremendous progress that has been made in the treatment landscape for cancer in the last 20 years, the need for additional, effective treatment options remains. Alector is leveraging its knowledge of the innate immune system, with the goal of developing novel, first-in-class therapies for patients who need new treatments.

AboutAlectorAlectoris a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Companyis developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.The Companys immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. This scientific approach is also the basis for the Companys immuno-oncology programs.Alectoris headquartered inSouthSan Francisco, California. For additional information, please visitwww.alector.com.

ContactsMedia:Erica JeffersonVice President, Communications and Public AffairsAlector, Inc.301-928-4650erica.jefferson@alector.com

1ABDan Budwick973-271-6085dan@1abmedia.com

or

Investors:Alector, Inc.ir@alector.com